The Little Known Cause of NAFLD That No One Is Talking About

Disclaimer: All supplement and test recommendations listed in this article are based on published and publicly available research literature. It is highly advised that you first speak with your physician to determine if any of these tests are right for you.

Let’s be honest, when we talk about liver health, we usually focus on what’s happening in the main office, the liver itself. We track our enzymes, monitor our fat intake, and obsess over glucose spikes. But the uncomfortable reality is that the liver doesn’t exist in a vacuum. It is downstream from many processes, and its most demanding neighbor is the gut.

If you’ve been doing everything right, eating the greens, skipping the sugar, and tracking your movement, but still feel like your metabolic health has stalled, it might be time to look at the relationship between your small intestine and your liver. Specifically, we need to talk about SIBO, or small intestinal bacterial overgrowth.

While we often think of SIBO as just a bloating issue, it is increasingly becoming a focal point in the management of NAFLD, or Non-Alcoholic Fatty Liver Disease. It’s a nuanced, often overlooked connection that proves our metabolic balance is only as stable as our gut-liver axis.

I’m Not Overweight, Why Do I Have NAFLD?

It is a common misconception that fatty liver is exclusively a consequence of overconsuming calories, but for those navigating “Lean NAFLD“, the diagnosis can feel like a cruel joke.

When your BMI is in the normal range and your blood sugar, blood pressure, and triglycerides pass every test with flying colors, the source of liver fat is often a more nuanced, upstream issue, potentially SIBO.

Even without the traditional markers of metabolic syndrome, a small intestine overcrowded with bacteria acts as a constant inflammatory trigger (Younossi et al., 2018). These bacteria produce bacterial endotoxins, or LPS, that breach the intestinal barrier and travel directly to the liver via the portal vein.

Once there, they activate toll-like receptor 4, signaling the liver to accumulate fat as a protective, albeit damaging, response to this chronic toxic exposure(Sookoian & Pirola, 2011). This means that even in a lean body, the liver is being forced into a state of metabolic distress by an upstream process (Miele et al., 2009).

SIBO often bypasses the traditional red flags of metabolic disease, and testing for it in the context of NAFLD often is overlooked. If you don’t exhibit the traditional hallmark symptoms of SIBO, it’s easy to rationalize other key players in your liver health like diet, alcohol consumption and movement.

How the Gut Talks to the Liver

The relationship between your gut and your liver is essentially a direct pipeline called the portal vein. Nearly everything that leaves your digestive tract – nutrients, toxins, and bacterial byproducts, goes straight to the liver for its final audit before entering the rest of your bloodstream. The liver plays a critical and life-saving role as main gatekeeper to the bloodstream.

In a healthy system, this is a sophisticated filtration process. But when you have SIBO, the small intestine is overcrowded with bacteria that shouldn’t be there, or should be there but in lesser amounts. These bacteria produce metabolic byproducts that essentially pollute the pipeline.

Research published in the World Journal of Gastroenterology highlights that SIBO is significantly more prevalent in patients with NAFLD compared to the general population, with some studies suggesting a prevalence rate as high as 50% to 78% in those with chronic liver issues (Miele et al., 2009).

LPS, The Internal Inflammatory Trigger

The primary bad actor in the SIBO-NAFLD connection is something called Lipopolysaccharide, or LPS. These are endotoxins found in the cell walls of certain bacteria. When these bacteria overgrow in the small intestine, they don’t just stay there, they damage the delicate lining of the gut, creating what we commonly call leaky gut, or increased intestinal permeability.

Once the barrier is breached, LPS hitches a ride on the portal vein directly to the liver. Once there, they trigger receptor 4, or TLR4, which acts like a biological alarm bell. This alarm triggers a cascade of inflammation and oxidative stress, telling the liver to inflame, and the more it is inflamed, the more fat the liver will store rather than processing it (Giorgio et al., 2014).

Essentially, SIBO keeps your liver in a state of constant inflammation, making it nearly impossible for the organ to focus on its primary job, metabolic regulation.

The Internal Brewery, Endogenous Ethanol

One of the most fascinating, and frustrating, aspects of SIBO is the production of endogenous ethanol. Certain strains of bacteria in a SIBO-impacted gut can ferment carbohydrates into alcohol right inside your small intestine.

Even if you haven’t had a drink in years, these bacteria can basically create a brewery in your gut. This internal ethanol production acts as a direct hepatotoxin, further contributing to fat accumulation and liver cell damage (Zhu et al., 2013).

This is often why NAFLD and Alcoholic Liver Disease can look so similar under a microscope, the liver is being hit with the same toxic load, just from a different source.

This is also why a low carb diet can often bring sustained relief to patients when other diets have inexplicably failed- because the direct cause of their NAFLD was never calories, it was sugar fermented into alcohol in the gut.

Navigating the SIBO – Liver Connection

If you suspect this gut-liver mismatch is part of your story, it requires a bespoke approach. You can’t just treat the liver and ignore the gut, nor can you treat the gut with mainstream high fiber advice that might actually feed the overgrowth.

1. Prioritize Barrier Integrity: To stop the flow of LPS to the liver, focus on nutrients like glutamine and zinc carnosine, which help maintain the tight junctions of the intestinal lining.
2. Strategic Fiber Management: While fiber is a metabolic darling, in the context of SIBO, high FODMAP foods like garlic, onions, and certain legumes can actually fuel the fire. Opt for gut safe fibers like partially hydrolyzed guar gum, or PHGG, which has been shown to support SIBO treatment without causing massive fermentation spikes (Furnari et al., 2010).
3. Prokinetic Support: SIBO is occasionally be a motility issue. If your gut is moving too slowly, bacteria have time to set up shop. Natural prokinetics like ginger and artichoke can help keep things moving, which in turn reduces the toxic load heading toward your liver.

What Tests Should I Get To See If SIBO Is Causing My NAFLD?

Identifying SIBO isn’t always a straightforward process, it requires a meticulous approach to catch the bacterial overgrowth that might be silently impacting your liver’s metabolic abilities.

Here are the primary tests your doctor can order to determine if SIBO is the hidden driver behind your NAFLD:

1. Hydrogen and Methane Breath Testing

This is the most common, non-invasive method for identifying SIBO. You’ll be asked to drink a sugar solution, usually lactulose or glucose, and then provide breath samples over a period of two to three hours. If bacteria are present in the small intestine, they ferment the sugar and produce hydrogen or methane gases, which are then absorbed into your blood and exhaled through your lungs.

• The Benefit: It’s a simple way to see if there is fermentation happening in your small intestine.
• The Nuance: The type of gas produced can actually tell your doctor which specific antimicrobial protocol might be the most bespoke fit for your system (Rezaie et al., 2017).

2. Small Bowel Aspiration and Culture

While the breath test is common, this is considered the gold standard for SIBO diagnosis. During an upper endoscopy, a small sample of fluid is taken directly from the duodenum (the first part of the small intestine) and sent to a lab to see how much bacteria actually grows.

• The Benefit: It is the most definitive way to prove that the bacterial count has exceeded the healthy threshold.
• The Nuance: Because it requires an invasive procedure, it’s usually reserved for cases where other markers are inconclusive but the clinical suspicion remains high (Khoshini et al., 2008).

3. Intestinal Permeability (Zonulin) Testing

Zonulin is a protein that regulates the openings between the cells of your intestinal lining. High levels of zonulin in the blood or stool are a strong indicator of leaky gut, the mechanism that allows LPS and other toxins to reach your liver.

• The Benefit: It validates whether the toxins are potentially infiltrating the liver.
• The Nuance: High zonulin levels are frequently found in patients with both SIBO and NAFLD, acting as the bridge between the two conditions (Valitutti et al., 2015).

4. High-Sensitivity C-Reactive Protein (hs-CRP)

While this isn’t a direct test for SIBO, it is a critical marker for systemic inflammation. In the case of Lean NAFLD, where other metabolic markers like blood sugar are normal, a high hs-CRP can signal that the liver is under stress from an external source, like bacterial translocation from the gut. High ferritin with normal iron saturation is another key sign that your liver is inflamed.

• The Benefit: it provides a clear picture of the inflammatory load your liver is currently trying to manage (Loffredo et al., 2020).

The Takeaway

Managing NAFLD isn’t just about what you eat, it’s about what your gut does with what you eat. By addressing SIBO and calming the gut-liver axis, your liver can get to a point where it can start releasing fat, in addition to restoring the integrity of your entire metabolic system.

It’s about making sure the commute between your gut and your liver is as clean and efficient as possible. Because when your gut is at peace, your liver finally has the space to do what it does best, help you live!

---

Disclaimer

The information, research, and recommendations presented in this article are for informational and educational purposes only and do not constitute medical advice, diagnosis, or treatment. While I aim to provide a clear and accessible interpretation of current, publicly available scientific literature, this content is not a substitute for professional medical consultation. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition, specifically before starting any new supplement, diagnostic test, or lifestyle change. Scientific research is dynamic and constantly evolving, therefore, relying on any information provided in this article is solely at your own volition. These findings should be viewed as a nuanced starting point for a conversation with your medical team rather than a definitive or diagnostic protocol.

Citations

• Miele, L., et al. (2009). Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease. World Journal of Gastroenterology.
• Giorgio, V., et al. (2014). The link between intestinal dysbiosis and liver disease. Clinical and Molecular Hepatology.
• Zhu, L., et al. (2013). Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology.
• Furnari, M., et al. (2010). The role of partially hydrolyzed guar gum in the treatment of small intestinal bacterial overgrowth. Journal of Clinical Gastroenterology.
• Younossi, Z. M., et al. (2018). Global epidemiology of nonalcoholic fatty liver disease, A systematic review and meta, analysis. Hepatology.
• Sookoian, S., & Pirola, C. J. (2011). Nonalcoholic fatty liver disease is not always a fat man’s disease, The case of lean nonalcoholic fatty liver disease. Annals of Hepatology.
• Miele, L., et al. (2009). Small intestinal bacterial overgrowth and non, alcoholic fatty liver disease. World Journal of Gastroenterology.
• Rezaie, A., et al. (2017). Hydrogen and methane, based breath testing in gastrointestinal disorders, The North American Consensus. The American Journal of Gastroenterology.
• Khoshini, R., et al. (2008). A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Digestive Diseases and Sciences.
• Valitutti, F., et al. (2015). Intestinal permeability and non, alcoholic fatty liver disease, The role of zonulin. World Journal of Gastroenterology.
• Loffredo, L., et al. (2020). Gut, derived lipopolysaccharide and non, alcoholic fatty liver disease, A systematic review and meta, analysis. Journal of Gastroenterology and Hepatology.